Translational Cell And Tissue Regenerative Medicine Summit

The Translational Cell and Tissue Regenerative Medicine Summit is your premiere forum to network with 80+ industry experts for the first time. Gain an unrivalled overview of the translational and clinical development landscape, and explore novel approaches to regenerate tissue topography through cell and tissue transplant.

Developed in collaboration with key research and clinical development teams from Organmet Bio, AstraZeneca, Sana Bio, Nestle Research, GC Therapeutics, Boehringer Ingelheim and more. Leave this meeting with key lessons learned to design therapies with clinical utility, and optimize CMC and manufacturing for safe, efficacious tissue therapies.

URLs:
Website: https://go.evvnt.com/1452306-0?pid=10018
Tickets: https://go.evvnt.com/1452306-2?pid=10018
Brochure: https://go.evvnt.com/1452306-3?pid=10018

Prices:
Drug Developer Pricing - Conference + 3 Workshops: USD 4946.00,
Drug Developer Pricing - Conference + 2 Workshops: USD 4297.00,
Drug Developer Pricing - Conference + 1 Workshop: USD 3648.00,
Drug Developer Pricing - Conference Only: USD 2999.00,
Academic Pricing - Conference + 3 Workshops: USD 4246.00,
Academic Pricing - Conference + 2 Workshops: USD 3697.00,
Academic Pricing - Conference + 1 Workshop: USD 3148.00,
Academic Pricing - Conference Only: USD 2599.00

Speakers: David Hoffmann, Co-Founder, Angios GmbH, Tamer Mohamed, Founder and Chief Executive Officer, Aspect Biosystems Ltd., Mike Doran, Director - Cell Therapy, AstraZeneca, Tania Incitti, Associate Principal Scientist, AstraZeneca, Norman Kim, VP Preclinical Safety and Toxicology, BlueRock Therapeutics, Antonio Filareto, Principle Scientist - Regenerative Medicine, Boehringer Ingelheim, Wenning Qin, VP Genome Editing, eGenesis, Alex Ng, Co-founder and Chief Scientific Officer, GC Therapeutics, John Barry, Vice President - Research and Development, Miromatrix, Omid Mashinchian, Team Leader - Precision Regenerative Medicine, Bioengineering, Research and Development Expert, Nestle Research, Alain Vertes, Managing Director, NxR Biotechnologies GmbH, Doris Taylor, Chief Executive Officer, Organamet Bio, Nitsan Halevy, Chief Medical Officer, Pluristem Therapeutics, Inc, Fabian Zanella, Director of Analytical Testing in Cell Therapy and Regenerative Medicine, Sana Biotechnology, Eugene Boland, Director Site Quality, Talaris Therapeutics, Hassan Rashidi, Senior Research Associate in Stem Cell and Regenerative Medicine, University College London, Stephen Badylak, Professor - Departments of Surgery and Bioengineering, University of Pittsburgh, Ivana Barbaric, Senior Lecturer, University of Sheffield, Graça Almeida-Porada, Professor and Director of Fetal Research and Therapy Program, Wake Forest Institute for Regenerative Medicine